DRI Healthcare Reports Third Quarter 2025 Results
Executive Summary
- DRI Healthcare Trust reported Q3 2025 results, posting Total Income of $48.7 M and Adjusted EBITDA of $36.7 M (84% margin).
- Completed a $300 M royalty acquisition from Viridian Therapeutics, funding $55 M upfront plus up to $115 M in milestones; the deal provides tiered royalties of 7.50% on U.S. net sales up to $600 M and lower rates thereafter.
- Internalized its investment‑management function (terminated Persis Capital agreement for a $48 M fee) and repurchased 393,618 units under its NCIB for $4.1 M; an additional 53,076 units were bought post‑quarter.
Key Details
- Financial Highlights (Q3 2025)
- Total Income: $48.7 M (up 17% YoY)
- Adjusted EBITDA: $36.7 M (84% margin)
- Comprehensive loss: $(57.7 M)
-
Adjusted cash earnings per unit: $0.55 (basic & diluted)
-
Royalty Acquisition – Veligrotug & VRDN‑003
- Purchase price: up to $300 M (includes $55 M upfront, up to $115 M near‑term milestones)
- Royalty rates: 7.50% on U.S. net sales ≤ $600 M; 0.80% on $600–$900 M; 0.25% on $900 M–$2 B
-
First royalty receipt to begin the quarter after first U.S. commercial sale
-
Internalization of Investment Management
- Terminated Persis Capital management agreement – termination fee $48 M
-
Acquired relevant assets from Persis for $1 M
-
Ekterly Funding Update
-
One‑time optional payment of $22 M increased royalty entitlement to 6.0% on the first $500 M of net sales; total investment in Ekterly now $127 M
-
NCIB Activity
- Repurchased 393,618 units at avg. $10.30 per unit (total $4.1 M) during quarter
-
Additional post‑quarter repurchase of 53,076 units at avg. $10.28 ($0.5 M)
-
Distributions
- Quarterly cash distribution of $0.10 per unit paid 20 Oct 2025 (Q3)
-
Declared Q4 distribution of $0.10 per unit, payable 20 Jan 2026
-
Liquidity & Capital Structure
- Cash & equivalents: $35.6 M (30 Sep 2025)
- Credit facility balance: $347.8 M outstanding; acquisition credit facility increased by $70 M, extending maturity to 3 Oct 2029
-
Drew $50 M from the facility to fund the royalty transaction
-
Portfolio Overview (as of 30 Sep 2025)
- 28 royalty streams on 21 products; book value of royalty assets $756.4 M (net of amortization)
-
Total cash royalty receipts Q3: $43.6 M; nine‑month total $145.8 M
-
Conference Call – Thursday, 6 Nov 2025 at 8:00 a.m. ET; webcast available at https://emportal.ink/4pOw5uK
Notable Quotes
“Following a transformative period… the recently announced acquisition underscores our disciplined and efficient approach to capital deployment…” – Ali Hedayat, CEO
Materiality Assessment: Material – Neutral** (Quarterly earnings and a $300 M royalty acquisition are material to investors; impact on net loss offsets positive cash generation.)